



Medical

10.4116

## Pall Ultipor™ 100



### *Breathing System Filter*

- ▶ Pleated hydrophobic membrane
- ▶ Smooth housing profile
- ▶ Optimal humidification
- ▶ Compatible with nebulisation
- ▶ 100% retentive for liquid-borne contaminants
- ▶ Retains natural rubber latex allergens in solutions and in airborne particles
- ▶ Individually integrity and efficiency tested during manufacture

*Filtration. Separation. Solution.<sup>SM</sup>*

## Features and Benefits

- ▶ **Optimal humidification:** Physiological levels of humidification are maintained, even at high flow rates and in long term ventilation. Clinical humidification performance is comparable to hot water bath systems and hygroscopic HMEs.<sup>1,2,3,4</sup> Rheological and physical properties of patient airway mucus are preserved and physiological mucus clearance is maintained.<sup>5</sup>
- ▶ **Compatible with nebulisation:** Medications can be nebulised between the filter and the patient.
- ▶ **Effective hydrophobic barrier:** The pleated hydrophobic membrane provides effective protection against airborne and liquid-borne micro-organisms. This assures protection against cross-contamination between patients in anaesthesia<sup>6,7,8</sup> and can contribute to a reduction of ventilator associated pneumonia in long term intensive care ventilation.<sup>4</sup> The filter has been validated to remove *Mycobacterium tuberculosis*<sup>9</sup>, *Staphylococcus aureus*<sup>10</sup>, Hepatitis C virus<sup>7</sup> and HIV<sup>11</sup>. All Pall Breathing System Filters contain the proprietary Pall fine hydrophobic filter media, which has been tested in manufacturing to show a water intrusion pressure (hydrophobicity) in excess of 50 cm water column.  
  
Routine use of the Ultipor 100 will protect the interior of the breathing system from patient derived contamination, allowing extended use of the breathing system in conjunction with a hospital protocol that ensures hygienic and mechanical integrity of the system. Please refer to your breathing system manufacturer for information on whether the system being used has been validated for extended use.
- ▶ **Extended life:** When nebulisation is not used.
- ▶ **Latex safety:** The Pall Ultipor 100 is free of natural rubber latex. It has been tested to show retention of natural rubber latex allergens in liquids and contained in airborne particles.<sup>12,13</sup>

## Pall Total Quality and Performance Guarantee

Each Pall Ultipor 100 Breathing System Filter is individually tested during manufacture for:

- ▶ **Filter Integrity** – assuring housing and seal quality.
- ▶ **Filtration Efficiency** – using a non-destructive test, assuring membrane quality.

A Product Validation Certificate that is batch and customer specific can be provided to show details of testing and validation. This is the customer's guarantee of 100% reliability, performance in use and assurance of protection of breathing systems and equipment, patients and staff.

## Technical Data

|   |   |
|---|---|
| Filter material                                 | Pleated hydrophobic membrane  |
| Liquid-borne bacterial/viral removal efficiency | 100%  |
| Bacterial aerosol removal efficiency            | > 99.999%   |
| Humidification                                  | Water loss: 8 mg/L up to 800 mL tidal volume<br>Water loss: 9.5 mg/L @ 800 – 1000 mL tidal volume         |
| Resistance at 60 L/min                          | Approximately 2 cm water  |
| Construction                                    | Transparent, non-conductive   |
| Connections – ISO tapers                        | Patient side 15 mm ID + 22 mm OD<br>Breathing system side 22 mm ID  |
| Filter volume                                   | Approximately 85 mL   |
| Weight  | Approximately 47 g  |
| Recommended use                                 | 24 hr change. Use may be extended to 48 hr when nebulisation is not used.<br>Single use, patient end only |

## Ordering Information

| Reorder Code | Description                              |
|--------------|--|
| BB100E       | Pall Ultipor 100 Breathing System Filter |
| BB100P       | with monitoring port                     |

A range of catheter mounts and connectors are available. Consult your Pall representative for details.

Sterile variants: Order codes as above, add S for sterile product.

## References

1. F Tiger *et al.* Journal de la Société Francophone d'Urgences Médicales et de la Société de Réanimation de Langue Française 1994; 3: 6.
2. Nakagawa NK *et al.* *Clinical Intensive Care* 1995; 6: 2 supplement.
3. Martin C *et al.* Presented at the ATS/ALA meeting, Seattle USA, May 1995.
4. Kirton OC *et al.* *Chest* 1997; 112: 1055-59.
5. Nakagawa NK *et al.* *Crit Care Med* 2000; 28(2): 312-317
6. Association of Anaesthetists of Great Britain and Ireland. HIV and other blood borne viruses – guidance for anaesthetists. January 1996 Update.
7. Lloyd G *et al.* *Anaesthesia and Intensive Care* 1997; 25: 235-38.
8. Purday J. *Technic* 1997; 63: 9-11.
9. Speight S *et al.* Centre for Applied Microbiology and Research, 1995.
10. Rosales M & Dominguez V. 2nd International Conference on Prevention of Infection, Nice, France, 4-5th May 1992.
11. Lloyd G *et al.* Centre for Applied Microbiology and Research, 1997.
12. Barbara J *et al.* *Anaesthesia* 2001; 56: 231-234.
13. Chen Z & Capewell A. Scientific and Laboratory Services Report. Pall Europe 2000.



**Pall International Sàrl**  
Avenue de Tivoli 3  
1700 Fribourg, Switzerland


+41 (0)26 350 53 00 phone  
+41 (0)26 350 53 53 fax  
LifeSciences.EU@pall.com email

Visit us on the Web at [www.pall.com/medical](http://www.pall.com/medical)

### International Offices

Pall Corporation has offices and plants throughout the world in locations such as: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, France, Germany, India, Indonesia, Ireland, Italy, Japan, Korea, Malaysia, Mexico, the Netherlands, New Zealand, Norway, Poland, Puerto Rico, Russia, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, the United Kingdom, the United States and Venezuela. Distributors in all major industrial areas of the world. This document is not for distribution in the USA and Canada.

The information provided in this literature was reviewed for accuracy at the time of publication. Product data may be subject to change without notice. For current information consult your local Pall distributor or contact Pall directly.

© 2010, Pall Europe. Pall,  and Ultipor are trademarks of Pall Corporation. © indicates a trademark registered in the USA and TM indicates a common law trademark. **Filtration. Separation. Solution.** is a service mark of Pall Corporation